Primary Aldosteronism
Conditions
Keywords
Adrenal, Conn's, Endocrine, Aldosterone
Brief summary
The study is a Phase 1, single-centre, open label, micro-dosing study. The aim is to investigate an innovative new tracer, \[18F\]CETO, as a potential alternative to adrenal vein sampling for the lateralisation of primary aldosteronism (PA).
Detailed description
At least one-quarter of the UK adult population has hypertension, a major risk factor for heart attacks and stroke. Primary aldosteronism (PA), a treatable form of hypertension, accounts for 5-10% of all cases, and 20-25% of difficult to control hypertension. It is challenging to determine whether one adrenal gland is the source of PA (which is potentially curable with surgery) or both glands (which would require long-term drug treatment). Existing lateralising procedures (i.e. investigations to distinguish one from two gland involvement e.g. CT or MRI scan) have significant limitations. Accordingly, most patients must undergo an invasive procedure called adrenal vein sampling (AVS) in which small catheters are placed in each adrenal vein. However, this is time-consuming, technically demanding, and fails in 20-50% of cases. To address this, researchers have adopted a novel approach using PET-CT as an alternative to AVS. Currently, this uses a tracer called metomidate labelled with carbon-11 (11C MTO), which is taken up preferentially by the adrenal gland, and in particular by adrenal tumours causing PA. However, its utility is limited by a short half-life, which means the scan can only be performed in centres with a cyclotron facility (currently less than 10 NHS sites). The aim of this study is to investigate the safety of a new tracer with a longer half-life, \[18F\]CETO, that could be made available for use in many more centres. The trial objectives are outlined below: Primary Objective To evaluate the safety of up to two administrations of \[18F\]CETO in up to 6 patients with primary aldosteronism and 5 healthy volunteers. Secondary Objective * Assess \[18F\]CETO uptake by the adrenal glands * Evaluate uptake in bilateral vs unilateral cases of PA following \[18F\]CETO administration in up to 6 patients.
Interventions
COMBINATION_PRODUCT[18F]CETO
\[18F\]CETO is a PET radiotracer used to diagnose and visualise the cause(s) of primary aldosteronism
Sponsors
Cambridge University Hospitals NHS Foundation Trust
University of Cambridge
Study design
Allocation
NON_RANDOMIZED
Intervention model
PARALLEL
Primary purpose
DIAGNOSTIC
Masking
SINGLE (Outcomes Assessor)
Masking description
Scans will be assessed by two independent nuclear medicine physicians, who will be blinded to patient identifiable data when analysing PET-CT scans.
Intervention model description
Phase I single-centre, open-label, micro-dosing study
Eligibility
Sex/Gender
ALL
Age
40 Years to No maximum
Healthy volunteers
Yes
Inclusion criteria
Healthy Volunteers To be included in the trial the participant must: * give written informed consent * be aged 50 years or over * have no underlying medical conditions * be able to lie down for at least 2 hours and not be claustrophobic In addition, all female participants must be: \- post-menopausal (no menses for 12 months, without an alternative medical cause) Patients To be included in the trial the patient must: * give written informed consent * be aged 40 years or over * be able to lie down for at least 2 hours and not be claustrophobic fulfil the following criteria: * have a confirmed diagnosis of PA as per Endocrine Society guidelines * At least one paired measurement of plasma renin and aldosterone, measured off Spironolactone/Eplerenone within past 12 months, showing ARR above local threshold value. * One of the following two criteria: * Plasma aldosterone\>190pmol/L following saline infusion. * Spontaneous hypokalaemia, suppressed plasma renin and plasma aldosterone\>550pmol/L. * have undergone successful lateralisation of the cause of PA to one or both adrenal glands by adrenal vein sampling (AVS). * be willing to have two scans In addition, all female patients must have a negative (blood) pregnancy test at the screening visit.
Exclusion criteria
All participants: * allergy to radiographic contrast agents * allergy or contraindication to synacthen * pregnancy, breastfeeding, or the intention to become pregnant during the 6 months following trial participation * positive pregnancy test at the screening or baseline visits * assessed by the investigator as being unable or unwilling to comply with the requirements of the study protocol. * receipt of another IMP as part of a CTIMP * prior radiation exposure as part of previous research studies * recreational drug use, or substance/alcohol dependency * clinically abnormal screening blood tests. Additional
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Safety of [18F]CETO administration | 6 months | The primary outcome measure is the overall safety of \[18F\]CETO. This will be assessed according to the frequency of adverse events, serious adverse events, clinically significant changes in vital signs, ECG and laboratory parameters. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| [18F]CETO uptake by the the adrenal glands. | 6 months | \[18F\]CETO uptake by the adrenal glands will be assessed by measurement of Standardized Uptake Values (SUV) over the left and right adrenal glands. All assessments will be performed by a dedicated blinded reviewer. |
| To evaluate uptake in bilateral versus unilateral cases of PA following [18F]CETO administration in up to 6 patients. | 6 months | Evaluation of adrenal uptake of \[18F\]CETO in bilateral versus unilateral cases of PA will be performed by comparing SUV values of both adrenal glands in three patients with each subtype of PA (using a dedicated blinded reviewer). |
Countries
United Kingdom
Contacts
Primary ContactMartin Thomas, PhD
Backup ContactRussell Senanayake, MRCP, MSc
Outcome results
None listed